



NOTIFIABLE DISEASES IN NOVA SCOTIA 2020 AND 2021 SURVEILLANCE REPORT

ACKNOWLEDGEMENTS

Provincial notifiable disease surveillance would not be possible without the timely and complete case reporting by health care providers, public health professionals, and laboratories within the province. The Nova Scotia Department of Health and Wellness extends its thanks to all those whose contributions have helped make this report possible.

For questions regarding this report, contact:

Nova Scotia Department of Health and Wellness
PO Box 488
Halifax, NS B3J 2R8

Email: surveillancedhw@novascotia.ca

TABLE OF CONTENTS

INTRODUCTION	1
METHODS	2
LIMITATIONS	3
2020-2021 HIGHLIGHTS.....	4
Syphilis.....	4
HIV & AIDS.....	5
Lyme Disease	5
REFERENCES	6
APPENDIX A – Notifiable Diseases in Nova Scotia.....	7
APPENDIX B – List of Tables.....	8

INTRODUCTION

Surveillance is defined as the “systematic and continuous collection, analysis and interpretation of data closely integrated with the timely dissemination of the results and assessment to those who have the right to know so that action can be taken” (1).

In Nova Scotia, surveillance of notifiable diseases is governed by the provincial *Health Protection Act*, which mandates the reporting of diseases by many partners within the public health system and the health system as a whole (2). The list of current notifiable diseases in Nova Scotia can be found in Appendix A.

The purpose of this report is to provide a summary of notifiable diseases reported in Nova Scotia in 2020 and 2021. Due to the resource requirements of the ongoing COVID-19 response, the report will only provide highlights of notifiable disease data for 2020 and 2021, some comparisons to national data, and a limited number of summary tables (Appendix B).

METHODS

In Nova Scotia, reporting of notifiable disease cases is mandated by the *Health Protection Act* (2). As part of public health case management, public health staff document information about notifiable disease cases that can include demographic, clinical, exposure, risk factor, treatment, and laboratory information.

Cases are classified based on standardized case definitions and are reported to the Nova Scotia Department of Health and Wellness (DHW), for provincial surveillance purposes, through the electronic public health surveillance system, Panorama. Since the implementation of Panorama in December 2018, Nova Scotia has almost entirely shifted away from paper case report forms and now relies on electronic capture of most public health information. Data prior to 2018 were extracted from Application for Notifiable Disease Surveillance (ANDS/ANDI), and data from 2018 onwards were extracted from Panorama.

Further information on the case definitions, reporting procedures, and forms can be found in the Nova Scotia Surveillance Guidelines for Notifiable Diseases and Conditions (3). Information on public health case management and control measures can be found in the Nova Scotia Communicable Disease Control Manual (4).

Cases of notifiable diseases are generally reported and counted based on their place of residence at the time of diagnosis, with some exceptions. For more information on the guidelines for reporting and counting cases, refer to the Nova Scotia Surveillance Guidelines for Notifiable Diseases and Conditions (3). For chronic conditions (e.g. hepatitis C, HIV), only residents with a first-time diagnosis in Nova Scotia are included in this report. If information on previous diagnoses for a case is not available these cases are counted as Nova Scotia cases.

Dates presented in this report are based on the episode date assigned to the case. The episode date is the earliest known date, reflecting symptom onset or the closest available date (specimen collection date, clinical diagnosis date, or test result date).

Only cases meeting a confirmed case definition are included in this report, with the exception of Lyme disease, where probable cases are also included.

Data for encephalitis-viral, meningitis-viral, amebiasis, hepatitis E, yersiniosis, lymphogranuloma venereum, Q fever and toxoplasmosis are reported in Appendix B, Table 1 because these diseases were reportable until 2015. They are not included in Tables 2a-4b.

Positive cases identified through anonymous testing (e.g. from anonymous HIV testing programs, special research studies) are not included in this report. Anonymous positive test results are not routinely reported to public health. It is assumed that most HIV cases that were first identified through anonymous testing will be reported nominally to public health. Access to HIV treatment is not available through anonymous testing streams.

Rates were calculated using Statistics Canada population counts based on the 2016 Census by health region, released March 2022 (accessed November 2022). All Canadian notifiable disease data were obtained from the Public Health Agency of Canada (PHAC) and are cited where used.

This report does not contain any detailed influenza surveillance data. Influenza reporting can be found on the DHW website (<http://novascotia.ca/dhw/populationhealth/>). This report also does not contain detailed COVID-19 surveillance data. COVID-19 Epidemiological Summaries can be found on the Nova Scotia coronavirus website: (<https://novascotia.ca/coronavirus/alerts-notice/#epidemiologic-summaries>).

Notifiable disease case data are current as of November 9, 2022.

LIMITATIONS

The numbers cited in this report include only those cases reported to Public Health within Nova Scotia Health (NSH). This report may under-represent the true number of cases in the population. This is particularly relevant for diseases that may remain asymptomatic (e.g., chlamydia) and those that have a wide clinical spectrum and are challenging to diagnose (e.g., Lyme disease). For certain diseases, cases that experience severe illness are more likely to present for medical care and be diagnosed and reported to public health (e.g. invasive meningococcal disease). These diseases are likely well-captured in surveillance reporting. Additional limitations in surveillance data may also be present for specific diseases (e.g. misclassification of hepatitis B cases as acute or chronic).

Changes in case finding procedures (e.g. changes to laboratory testing methods) can result in an increase or decrease in the number of reported cases due solely to the change in testing methods, as opposed to true changes in the number of cases in Nova Scotia.

Data reported in 2020 and 2021 are likely an underrepresentation of the true burden of notifiable disease. Notifiable disease surveillance was impacted by the COVID-19 pandemic; there were changes in testing policies and, at different periods, *some* testing for *some* notifiable diseases ceased. There were also limited public health resources and public health management and data entry were affected, as well as access to the health system.

Case numbers and rates presented in this report are based on case information in Panorama with episode dates between January 1, 2020-December 31, 2021. These data are current as of November 9, 2022. As Panorama is a real-time surveillance system, numbers and rates reported here will change as new information is added to Panorama. National notifiable disease data from PHAC that are used as a comparator in this report are also subject to change.

2020-2021 HIGHLIGHTS

A total of 6,839 cases of notifiable diseases (including influenza, n=422; COVID-19, n=1,515) were reported in Nova Scotia in 2020 and 14,724 cases (including influenza, n=14; COVID-19, n=9,432) were reported in 2021. Removing these two diseases, a total of 4,902 and 5,278 cases of notifiable diseases were reported in Nova Scotia in 2020 and 2021, respectively. A summary of diseases included in each disease category can be found in the Nova Scotia Surveillance Guidelines for Notifiable Diseases and Conditions (<http://novascotia.ca/dhw/populationhealth/surveillanceguidelines/>).

As noted above, influenza and COVID-19 cases are not described any further in this report. Information on influenza can be obtained from the Annual Influenza Surveillance Report: (<http://novascotia.ca/dhw/populationhealth/>). Information on COVID-19 can be found on the Nova Scotia coronavirus website: (<https://novascotia.ca/coronavirus/alerts-notice/#epidemiologic-summaries>).

Excluding influenza and COVID-19, the three most common notifiable diseases, in both 2020 and 2021, were chlamydia, a sexually transmitted infection (STI), *Clostridium difficile*, and methicillin resistant *Staphylococcus Aureus* (MRSA). Rates of chlamydia were 219.9 per 100,000 population and 208.9 per 100,000 population in 2020 and 2021, respectively; rates of *Clostridium difficile* were 820 per 100,000 population and 962 per 100,000 population in 2020 and 2021 respectively, and rates of MSRA were 459 per 100,000 population and 574 per 100,000 population, respectively,

Three diseases are highlighted in this report: syphilis, HIV/AIDS, and lyme disease.

Syphilis

In 2020, there were 29 cases of infectious syphilis and 22 cases of non-infectious syphilis (or stage pending) reported in Nova Scotia. In 2021, there were 15 cases of infectious syphilis and 24 cases of non-infectious syphilis (or stage pending) reported in Nova Scotia. The reported rate of infectious syphilis in Nova Scotia was 3.0/100,000 population for 2020 and 1.5/100,000 population for 2021. This is a decrease from 2019 (5.7/100,000 population). It is also lower compared to the most recently available Canadian infectious syphilis rate from 2020 (24.7/100,000 population) (5). Note, the Canadian infectious syphilis rate has increased 385% between 2011 and 2020 (5). Confirmed early congenital syphilis cases increased from 1.3/100,000 live births in 2011 to 13.4/100,000 live births in 2020 in Canada (5). No cases of congenital syphilis were reported in Nova Scotia in 2020 or 2021.

Infectious syphilis was reported more often in males than females in both years. There were 25 cases in males reported in 2020 (86.2% of cases), and 14 cases in males reported in 2021 (93.3% of cases).

Those aged 25 to 39 years reported infectious syphilis most often in both years (n=15, 8.1/100,000 population in 2020; n=6, 3.2/100,000 population in 2021). In 2021 those aged 40-59 years also reported 6 cases of syphilis (2.3/100,000 population).

The majority of cases in 2020 occurred in Central Zone (n=18, 3.8/100,000 population). In 2021, the highest number of cases occurred in Eastern Zone (n=6, 3.8/100,000 population).

An outbreak of syphilis was declared province-wide on January 20, 2020. Between 2020 and 2021, three out of four health zones in the province experienced a decrease in reported cases of infectious syphilis.

Between 2010 and 2021, the reported rate of infectious syphilis was highest in 2013 (9.0/100,000 population) and reported rate of non-infectious syphilis was highest in 2014 (3.9/100,000 population).

HIV & AIDS

There were 13 newly diagnosed cases of HIV in 2020 (rate: 1.3/100,000 population) and 16 newly diagnosed cases of HIV in Nova Scotia in 2021 (rate: 1.6/100,000 population). This is a decrease from 2019 (rate: 1.9/100,000 population). This is also below the Canadian rate of HIV in the same time period (4.3/100,000 in 2020) (6).

The majority of HIV cases reported were in males and were between the ages of 25 and 59 years. Of the HIV cases in 2020, 53.8% of HIV cases were male and 76.9% were between the ages of 25 and 59 years. Of the cases in 2021, 81.3% were male, and 75.0% were between the ages of 25 and 59 years.

The following exposure histories were reported among confirmed HIV cases: gay/bisexual men who have sex with men (2021: 53.3%; 2020: 45.5%), heterosexual contact-sexual contact with a person at risk (2021: 13.3%; 2020: 9.1%), and persons who use injection drugs (2021: 26.7%; 2020: 36.4%).

Between 2010 and 2021, the reported rate of HIV was highest in 2018 (3.2/100,000 population).

There was one new case of AIDS reported in Nova Scotia in 2020 (0.1/100,000 population) and no new cases in 2021. Between 2010 and 2021, the reported rate of AIDS was highest in 2010 (0.5/100,000 population).

Lyme Disease

There were 445 cases of confirmed and probable Lyme disease reported in 2020 and 594 cases reported in 2021, which is a decrease from 2019 (n=837). The most recent Canadian rate of Lyme disease, from 2020 (3.8/100,000 population), was lower compared to the 2020 and 2021 Nova Scotia rate (2020: 45.3/100,000 population; 2021: 59.9/100,000 population) (7).

In 2020, Western Zone had the highest rate among the zones (n=233; 116.8/100,000 population). In 2021, Central Zone had the highest rate among the zones (n=343; 71.2/100,000 population). In 2020 and 2021, those aged 60+ reported the highest number of cases (2020: n=192, 67.4/100,000 population; 2021: n=218, 74.4/100,000 population).

In 2020, 54.6% of the cases were male and in 2021, 55.4% of the cases were male.

Between 2010 and 2021, the reported rate of Lyme disease was highest in 2019 (86.2/100,000 population).

REFERENCES

1. Porta, M. (editor). (2014). *A Dictionary of Epidemiology*. Sixth Edition. Oxford University Press, New York.
2. Office of the Legislative Counsel, Nova Scotia House of Assembly. (2006). *Nova Scotia Health Protection Act, 2004, c. 4, s. 1*. Retrieved from <http://nslegislature.ca/legc/statutes/health%20protection.pdf>
3. Nova Scotia Department of Health and Wellness. (2013). *Nova Scotia Surveillance Guidelines for Notifiable Diseases and Conditions*. Retrieved from <http://novascotia.ca/dhw/populationhealth/surveillanceguidelines/>
4. Communicable Disease Prevention and Control, Nova Scotia Department of Health and Wellness. (2013). *Nova Scotia Communicable Disease Control Manual*. Retrieved from <http://novascotia.ca/dhw/cdpc/cdcmanual.asp>
5. Canada Communicable Disease Report (CCDR), *Rising syphilis rates in Canada, 2011-2020*. Retrieved from <https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-2-3-february-march-2022/syphilis-canada-2011-2020.html>
6. Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada (2022). *HIV in Canada, Surveillance Report to December 31, 2020*. Retrieved from <https://www.canada.ca/en/public-health/services/publications/diseases-conditions/hiv-canada-surveillance-report-december-31-2020.html>
7. Notifiable Disease On-line, Canadian Notifiable Disease Surveillance System, Public Health Agency of Canada. (2022). Retrieved from <http://dsol-smed.phac-aspc.gc.ca/dsol-smed/ndis/index-eng.php>

APPENDIX A – Notifiable Diseases in Nova Scotia

Acquired Immunodeficiency Syndrome (AIDS)	Meningitis (bacterial)
Acute Flaccid Paralysis (AFP)	Meningococcal Disease Invasive (IMD)
Anthrax*	Methicillin-resistant Staphylococcus aureus (MRSA)
Botulism (Foodborne, Wound, Infant, & Colonization Botulism)	Mumps
Brucellosis*	Pertussis
Campylobacteriosis	Plague*
Chlamydia (genital, extra-genital, and perinatally acquired)	Pneumococcal Disease, Invasive
Cholera*	Poliomyelitis*
Clostridium difficile	Rabies*
Creutzfeldt-Jakob Disease – Classic (sporadic, iatrogenic, Genetic Prion Disease) and Variant	Rubella (Non-Congenital, Congenital Rubella Syndrome)*
Cryptosporidiosis	Salmonellosis (includes Paratyphoid)
Cyclosporiasis	SARS-CoV-2 (COVID-19)
Diphtheria*	Severe Acute Respiratory Infection (SARI)
Ebola Virus Disease*	Severe Acute Respiratory Syndrome (SARS)
Giardiasis	Shellfish Poisoning (Paralytic & Amnesic)*
Gonorrhea (genital, extra-genital, and perinatally acquired)	Shigellosis
Group A Streptococcal Disease, Invasive	Smallpox*
Group B Streptococcal Disease of Newborn	Syphilis (primary, secondary, early latent, late latent, infectious neurosyphilis, non-infectious neurosyphilis, tertiary other than neurosyphilis, and early congenital)
Haemophilus Influenzae type b (Hib) Invasive Disease	Tetanus
Hantavirus Pulmonary Syndrome (HPS)*	Tuberculosis
Hepatitis A	Tularemia*
Hepatitis B (Acute Case and Chronic Carrier)	Typhoid
Hepatitis C	Vancomycin Resistant Enterococcus (VRE)
Human Immunodeficiency Virus (HIV)	Verotoxigenic Escherichia coli
Influenza (laboratory confirmed)	Viral Hemorrhagic Fevers* (Lassa, Marburg, Crimean-Congo, Other)
Listeriosis (Invasive)	West Nile Virus (WNV) (West Nile Asymptomatic Infection, West Nile Neurological Syndrome, West Nile Non-Neurological Syndrome)
Legionellosis	Yellow Fever*
Leprosy (Hansen’s Disease)*	
Lyme Disease	
Malaria (Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax)	
Measles	

APPENDIX B – List of Tables

TABLE 1: Notifiable diseases reported in Nova Scotia from 2012-2021: Number of reports and crude rates per 100,000 population	9
TABLE 2a: Notifiable diseases reported in Nova Scotia in 2020 by Health Management Zone: Number of reports and crude rates per 100,000 population	10
TABLE 2b: Notifiable diseases reported in Nova Scotia in 2021 by Health Management Zone: Number of reports and crude rates per 100,000 population	11
TABLE 3a: Notifiable diseases reported in Nova Scotia in 2020 by age group: Number of reports and age specific rates per 100,000 population	12
TABLE 3b: Notifiable diseases reported in Nova Scotia in 2021 by age group: Number of reports and age specific rates per 100,000 population	13
TABLE 4a: Notifiable diseases reported in Nova Scotia in 2020: Number of reports and sex-specific rates per 100,000 population	14
TABLE 4b: Notifiable diseases reported in Nova Scotia in 2021: Number of reports and sex-specific rates per 100,000 population	15

TABLE 1: Notifiable diseases reported in Nova Scotia from 2012-2021: Number of reports and crude rates per 100,000 population

Condition	Year																		All Years			
	2012		2013		2014		2015		2016		2017		2018		2019		2020		2021		n	Average Rate
	n	Rate	n	Rate	n	Rate	n	Rate	n	Rate	n	Rate	n	Rate	n	Rate	n	Rate				
Bloodborne Pathogens																						
Acquired Immune Deficiency Syndrome (AIDS)	2	0.2	0	0.0	4	0.4	3	0.3	2	0.2	1	0.1	0	0.0	0	0.0	1	0.1	0	0.0	13	0.1
Hepatitis B - Acute	1	0.1	2	0.2	3	0.3	9	1.0	9	0.9	6	0.6	6	0.6	4	0.4	6	0.6	3	0.3	49	0.5
Hepatitis B-Chronic	9	1.0	13	1.4	21	2.2	10	1.1	12	1.3	18	1.9	21	2.2	21	2.2	14	1.4	19	1.9	158	1.7
Hepatitis C	252	26.6	289	30.7	332	35.4	362	38.4	296	31.2	295	30.9	348	36.3	354	36.4	257	26.2	278	28.0	3063	32.0
Human Immunodeficiency Virus (HIV)	17	1.8	16	1.7	10	1.1	17	1.8	21	2.2	15	1.6	31	3.2	18	1.9	13	1.3	16	1.6	174	1.8
Direct Contact, Respiratory Routes, and Through the Provision of Health Care																						
Clostridium difficile	500	52.8	676	71.9	610	65.0	812	86.1	879	92.6	927	97.2	984	102.5	907	93.4	820	83.5	962	97.0	8077	84.2
Creutzfeldt-Jakob Disease - Classic	3	0.3	1	0.1	2	0.2	0	0.0	1	0.1	1	0.1	0	0.0	2	0.2	0	0.0	0	0.0	10	0.1
Encephalitis - Viral**	1	0.1	0	0.0	1	0.1	2	0.2	-	-	-	-	-	-	-	-	-	-	-	-	4	0.1
Group A Streptococcal Disease Invasive-Severe	11	1.2	6	0.6	8	0.9	10	1.1	6	0.6	16	1.7	21	2.2	18	1.9	6	0.6	3	0.3	105	1.1
Group A Streptococcal Disease Invasive-non-Severe	13	1.4	15	1.6	14	1.5	15	1.6	12	1.3	30	3.1	36	3.8	41	4.2	16	1.6	5	0.5	197	2.1
Group B Streptococcal Disease of the Newborn	1	0.1	3	0.3	1	0.1	3	0.3	3	0.3	3	0.3	5	0.5	3	0.3	0	0.0	0	0.0	22	0.2
Legionellosis	0	0.0	2	0.2	3	0.3	7	0.7	1	0.1	9	0.9	5	0.5	7	0.7	6	0.6	15	1.5	55	0.6
Meningitis - Bacterial	0	0.0	0	0.0	2	0.2	0	0.0	0	0.0	1	0.1	0	0.0	1	0.1	0	0.0	0	0.0	4	0.0
Meningitis - Viral**	39	4.1	20	2.1	15	1.6	17	1.8	-	-	-	-	-	-	-	-	-	-	-	-	91	2.4
Meningococcal Disease Invasive	2	0.2	0	0.0	3	0.3	7	0.7	4	0.4	6	0.6	4	0.4	7	0.7	3	0.3	2	0.2	38	0.4
Methicillin Resistant Staphylococcus Aureus (MRSA)	835	88.2	787	83.7	644	68.6	623	66.1	569	59.9	522	54.7	624	65.0	600	61.8	459	46.7	574	57.9	6237	65.3
Pneumococcal Disease Invasive	51	5.4	65	6.9	66	7.0	52	5.5	66	7.0	49	5.1	61	6.4	125	12.9	50	5.1	87	8.8	672	7.0
Tuberculosis	8	0.8	8	0.9	7	0.7	6	0.6	3	0.3	9	0.9	9	0.9	7	0.7	12	1.2	15	1.5	84	0.9
Vancomycin resistant Enterococcus (VRE)	49	5.2	43	4.6	17	1.8	4	0.4	13	1.4	121	12.7	31	3.2	24	2.5	8	0.8	9	0.9	319	3.4
Enteric, Foodborne, and Waterborne Diseases																						
Amebiasis**	4	0.4	3	0.3	3	0.3	6	0.6	-	-	-	-	-	-	-	-	-	-	-	-	16	0.4
Botulism	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	188	19.9	172	18.3	181	19.3	155	16.4	170	17.9	185	19.4	204	21.3	221	22.8	192	19.6	285	28.7	1953	20.4
Cryptosporidiosis	18	1.9	22	2.3	32	3.4	17	1.8	27	2.8	41	4.3	41	4.3	40	4.1	34	3.5	19	1.9	291	3.0
Cyclosporiasis	0	0.0	3	0.3	1	0.1	3	0.3	2	0.2	2	0.2	2	0.2	1	0.1	0	0.0	0	0.0	14	0.1
Giardiasis	96	10.1	96	10.2	91	9.7	87	9.2	100	10.5	93	9.7	75	7.8	107	11.0	88	9.0	99	10.0	932	9.7
Hepatitis A	2	0.2	2	0.2	3	0.3	1	0.1	11	1.2	2	0.2	4	0.4	4	0.4	2	0.2	3	0.3	34	0.4
Hepatitis E**	0	0.0	0	0.0	0	0.0	0	0.0	-	-	-	-	-	-	-	-	-	-	-	-	0	0.0
Listeriosis - Invasive	4	0.4	8	0.9	5	0.5	8	0.8	4	0.4	4	0.4	3	0.3	2	0.2	3	0.3	4	0.4	45	0.5
Salmonellosis	150	15.8	169	18.0	204	21.7	169	17.9	138	14.5	171	17.9	184	19.2	131	13.5	152	15.5	95	9.6	1563	16.4
Shigellosis	11	1.2	1	0.1	9	1.0	5	0.5	10	1.1	10	1.0	4	0.4	7	0.7	1	0.1	4	0.4	62	0.7
Typhoid	0	0.0	1	0.1	2	0.2	0	0.0	1	0.1	2	0.2	0	0.0	1	0.1	0	0.0	0	0.0	7	0.1
Verotoxigenic E. coli	18	1.9	11	1.2	10	1.1	5	0.5	5	0.5	21	2.2	5	0.5	10	1.0	2	0.2	6	0.6	93	1.0
Yersiniosis**	3	0.3	3	0.3	2	0.2	2	0.2	-	-	-	-	-	-	-	-	-	-	-	-	10	0.3
Sexually Transmitted Infections																						
Chlamydia	2614	276.2	2466	262.1	2631	280.2	2865	303.8	2930	308.6	2988	313.3	3277	341.4	3179	327.3	2159	219.9	2072	208.9	27181	284.2
Gonorrhea	119	12.6	97	10.3	111	11.8	131	13.9	202	21.3	233	24.4	309	32.2	239	24.6	88	9.0	67	6.8	1596	16.7
Lymphogranuloma Venereum**	0	0.0	0	0.0	0	0.0	1	0.1	-	-	-	-	-	-	-	-	-	-	-	-	1	0.0
Syphilis - Infectious	68	7.2	85	9.0	63	6.7	44	4.7	20	2.1	26	2.7	32	3.3	55	5.7	29	3.0	15	1.5	437	4.6
Syphilis - Non-Infectious or Stage Pending	10	1.1	23	2.4	37	3.9	27	2.9	17	1.8	12	1.3	18	1.9	28	2.9	22	2.2	24	2.4	218	2.3
Vaccine Preventable Diseases																						
Acute Flaccid Paralysis	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
Haemophilus influenzae Type b Invasive Disease	1	0.1	1	0.1	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	3	0.0
Measles	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	29	3.0	0	0.0	0	0.0	0	0.0	0	0.0	29	0.3
Mumps	0	0.0	2	0.2	1	0.1	6	0.6	1	0.1	21	2.2	77	8.0	2	0.2	0	0.0	0	0.0	110	1.1
Pertussis	22	2.3	4	0.4	11	1.2	110	11.7	63	6.6	45	4.7	3	0.3	6	0.6	13	1.3	1	0.1	278	2.9
Tetanus	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
Vectorborne and Other Zoonoses																						
Lyme Disease - Confirmed	35	3.7	121	12.9	69	7.3	129	13.7	165	17.4	307	32.2	250	26.0	441	45.4	233	23.7	506	51.0	2256	23.3
Lyme Disease - Probable	17	1.8	35	3.7	47	5.0	129	13.7	160	16.9	279	29.2	207	21.6	396	40.8	212	21.6	88	8.9	1570	16.3
Malaria	3	0.3	3	0.3	3	0.3	4	0.4	6	0.6	3	0.3	6	0.6	4	0.4	1	0.1	2	0.2	35	0.4
Q-Fever**	0	0.0	0	0.0	0	0.0	3	0.3	-	-	-	-	-	-	-	-	-	-	-	-	3	0.1
Toxoplasmosis**	0	0.0	1	0.1	3	0.3	1	0.1	-	-	-	-	-	-	-	-	-	-	-	-	5	0.1
West Nile Virus	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total Number	5178		5275		5283		5867		5933		6504		6887		7013		4902		5278		58116	

Notes: Notifiable diseases with no reported cases in the last 10 years (marked with a * in Appendix A) and influenza and COVID-19 cases are not included in this table. Notifiable diseases reportable until 2015 marked with ** in table.

TABLE 2a: Notifiable diseases reported in Nova Scotia in 2020 by Health Management Zone: Number of reports and crude rates per 100,000 population

Condition	Western		Northern		Eastern		Central		Nova Scotia	
	n	Rate	n	Rate	n	Rate	n	Rate	n	Rate
Bloodborne Pathogens										
Acquired Immune Deficiency Syndrome (AIDS)	0	0.0	0	0.0	0	0.0	1	0.2	1	0.1
Hepatitis B - Acute	0	0.0	0	0.0	2	1.2	4	0.8	6	0.6
Hepatitis B - Chronic	1	0.5	1	0.7	1	0.6	11	2.3	14	1.4
Hepatitis C	30	15.0	68	45.6	68	42.2	91	19.3	257	26.2
Human Immunodeficiency Virus (HIV)	1	0.5	1	0.7	3	1.9	8	1.7	13	1.3
Direct Contact, Respiratory Routes, and Through the Provision of Health Care										
Clostridium difficile	171	85.7	138	92.6	206	127.7	305	64.6	820	83.5
Creutzfeldt-Jakob Disease - Classic	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Group A Streptococcal Disease Invasive-Severe	1	0.5	1	0.7	0	0.0	4	0.8	6	0.6
Group A Streptococcal Disease Invasive-Non-Severe	1	0.5	2	1.3	1	0.6	12	2.5	16	1.6
Group B Streptococcal Disease of the Newborn	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Legionellosis	0	0.0	0	0.0	0	0.0	6	1.3	6	0.6
Meningitis - Bacterial	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Meningococcal Disease Invasive	0	0.0	0	0.0	0	0.0	3	0.6	3	0.3
Methicillin Resistant Staphylococcus Aureus (MRSA)	141	70.7	77	51.6	108	67.0	133	28.2	459	46.7
Pneumococcal Disease Invasive	4	2.0	5	3.4	11	6.8	30	6.4	50	5.1
Tuberculosis	2	1.0	0	0.0	1	0.6	9	1.9	12	1.2
Vancomycin resistant Enterococcus (VRE)	0	0.0	3	2.0	2	1.2	3	0.6	8	0.8
Enteric, Foodborne, and Waterborne Diseases										
Botulism	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	72	36.1	30	20.1	17	10.5	73	15.5	192	19.6
Cryptosporidiosis	7	3.5	12	8.0	2	1.2	13	2.8	34	3.5
Cyclosporiasis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Giardiasis	22	11.0	10	6.7	10	6.2	46	9.7	88	9.0
Hepatitis A	1	0.5	0	0.0	0	0.0	1	0.2	2	0.2
Listeriosis - Invasive	0	0.0	1	0.7	0	0.0	2	0.4	3	0.3
Salmonellosis	46	23.1	17	11.4	40	24.8	49	10.4	152	15.5
Shigellosis	0	0.0	0	0.0	0	0.0	1	0.2	1	0.1
Typhoid	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Verotoxigenic E. coli	0	0.0	1	0.7	0	0.0	1	0.2	2	0.2
Sexually Transmitted Infections										
Chlamydia	390	195.5	265	177.8	335	207.7	1169	247.6	2159	219.9
Gonorrhoea	12	6.0	2	1.3	7	4.3	67	14.2	88	9.0
Syphilis - Infectious	0	0.0	4	2.7	7	4.3	18	3.8	29	3.0
Syphilis - Non-Infectious or Stage Pending	2	1.0	2	1.3	0	0.0	18	3.8	22	2.2
Vaccine Preventable Diseases										
Acute Flaccid Paralysis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Haemophilus influenzae Type b Invasive Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Measles	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Pertussis	5	2.5	0	0.0	0	0.0	8	1.7	13	1.3
Tetanus	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vectorborne and Other Zoonoses										
Lyme Disease - Confirmed	62	31.1	49	32.9	5	3.1	117	24.8	233	23.7
Lyme Disease - Probable	171	85.7	8	5.4	2	1.2	31	6.6	212	21.6
Malaria	0	0.0	0	0.0	0	0.0	1	0.2	1	0.1
West Nile Virus	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
TOTAL	1142		697		828		2235		4902	

Note: Notifiable diseases with no reported cases in the last 10 years (marked with a * in Appendix A) and influenza and COVID-19 cases are not included in this table.

TABLE 2b: Notifiable diseases reported in Nova Scotia in 2021 by Health Management Zone: Number of reports and crude rates per 100,000 population

Condition	Western		Northern		Eastern		Central		Nova Scotia	
	n	Rate	n	Rate	n	Rate	n	Rate	n	Rate
Bloodborne Pathogens										
Acquired Immune Deficiency Syndrome (AIDS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis B - Acute	0	0.0	0	0.0	1	0.6	2	0.4	3	0.3
Hepatitis B - Chronic	0	0.0	1	0.7	3	1.9	15	3.1	19	1.9
Hepatitis C	32	15.9	68	45.3	55	34.4	123	25.6	278	28.0
Human Immunodeficiency Virus (HIV)	1	0.5	0	0.0	5	3.1	10	2.1	16	1.6
Direct Contact, Respiratory Routes, and Through the Provision of Health Care										
Clostridium difficile	215	107.1	163	108.6	250	156.3	334	69.4	962	97.0
Creutzfeldt-Jakob Disease - Classic	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Group A Streptococcal Disease Invasive-Severe	0	0.0	0	0.0	1	0.6	2	0.4	3	0.3
Group A Streptococcal Disease Invasive-Non-Severe	0	0.0	0	0.0	1	0.6	4	0.8	5	0.5
Group B Streptococcal Disease of the Newborn	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Legionellosis	0	0.0	0	0.0	0	0.0	15	3.1	15	1.5
Meningitis - Bacterial	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Meningococcal Disease Invasive	0	0.0	0	0.0	0	0.0	2	0.4	2	0.2
Methicillin Resistant Staphylococcus Aureus (MRSA)	166	82.7	99	65.9	154	96.3	155	32.2	574	57.9
Pneumococcal Disease Invasive	5	2.5	16	10.7	26	16.3	40	8.3	87	8.8
Tuberculosis	0	0.0	1	0.7	3	1.9	11	2.3	15	1.5
Vancomycin resistant Enterococcus (VRE)	1	0.5	2	1.3	2	1.3	4	0.8	9	0.9
Enteric, Foodborne, and Waterborne Diseases										
Botulism	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	108	53.8	44	29.3	27	16.9	106	22	285	28.7
Cryptosporidiosis	11	5.5	5	3.3	0	0	3	0.6	19	1.9
Cyclosporiasis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Giardiasis	32	15.9	10	6.7	13	8.1	44	9.1	99	10.0
Hepatitis A	1	0.5	0	0.0	2	1.3	0	0.0	3	0.3
Listeriosis - Invasive	0	0.0	0	0.0	3	1.9	1	0.2	4	0.4
Salmonellosis	26	13.0	7	4.7	22	13.8	40	8.3	95	9.6
Shigellosis	0	0.0	2	1.3	0	0.0	2	0.4	4	0.4
Typhoid	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Verotoxigenic E. coli	1	0.5	1	0.7	1	0.6	3	0.6	6	0.6
Sexually Transmitted Infections										
Chlamydia	377	187.8	258	171.8	312	195.1	1125	233.8	2072	208.9
Gonorrhoea	10	5.0	10	6.7	3	1.9	44	9.1	67	6.8
Syphilis - Infectious	2	1.0	2	1.3	6	3.8	5	1.0	15	1.5
Syphilis - Non-Infectious or Stage Pending	0	0.0	4	2.7	6	3.7	14	2.9	24	2.4
Vaccine Preventable Diseases										
Acute Flaccid Paralysis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Haemophilus influenzae Type b Invasive Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Measles	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	0	0.0	0	0.0	0	0	0	0.0	0	0.0
Pertussis	0	0.0	0	0.0	0	0	1	0.2	1	0.1
Tetanus	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vectorborne and Other Zoonoses										
Lyme Disease - Confirmed	11	5.5	155	103.2	26	16.3	314	65.2	506	51.0
Lyme Disease - Probable	32	15.9	4	2.7	23	14.4	29	6.0	88	8.9
Malaria	0	0.0	0	0.0	0	0.0	2	0.4	2	0.2
West Nile Virus	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
TOTAL	1031		852		945		2450		5278	

Note: Notifiable diseases with no reported cases in the last 10 years (marked with a * in Appendix A) and influenza and COVID-19 cases are not included in this table

TABLE 3a: Notifiable diseases reported in Nova Scotia in 2020 by age group: Number of reports and age-specific rates per 100,000 population

Condition	Age Group (Years)												Total NS	
	0-4		5-14		15-24		25-39		40-59		60+			
	n	Rate	n	Rate	n	Rate	n	Rate	n	Rate	n	Rate	n	Rate
Bloodborne Pathogens														
Acquired Immune Deficiency Syndrome (AIDS)	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	1	0.1
Hepatitis B - Acute	0	0.0	0	0.0	0	0.0	1	0.5	3	1.1	2	0.7	6	0.6
Hepatitis B - Chronic	0	0.0	0	0.0	0	0.0	8	4.3	3	1.1	3	1.1	14	1.4
Hepatitis C	2	4.7	0	0.0	23	20.2	129	70.1	83	31.6	20	7.0	257	26.2
Human Immunodeficiency Virus (HIV)	0	0.0	0	0.0	2	1.8	9	4.9	1	0.4	1	0.4	13	1.3
Direct Contact, Respiratory Routes, and Through the Provision of Health Care														
Clostridium difficile	5	11.8	13	13.8	42	37.0	64	34.8	174	66.2	522	183.3	820	83.5
Creutzfeldt-Jakob Disease - Classic	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Group A Streptococcal Disease Invasive-Severe	1	2.4	0	0.0	0	0.0	1	0.5	2	0.8	2	0.7	6	0.6
Group A Streptococcal Disease Invasive-Non-Severe	1	2.4	1	1.1	1	0.9	3	1.6	5	1.9	5	1.8	16	1.6
Group B Streptococcal Disease of the Newborn	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Legionellosis	0	0.0	0	0.0	0	0.0	0	0.0	2	0.8	4	1.4	6	0.6
Meningitis - Bacterial	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Meningococcal Disease Invasive	0	0.0	0	0.0	0	0.0	2	1.1	1	0.4	0	0.0	3	0.3
Methicillin Resistant Staphylococcus Aureus (MRSA)	3	7.1	4	4.2	22	19.4	61	33.1	92	35.0	277	97.3	459	46.7
Pneumococcal Disease Invasive	0	0.0	0	0.0	0	0.0	7	3.8	13	4.9	30	10.5	50	5.1
Tuberculosis	0	0.0	0	0.0	3	2.6	3	1.6	6	2.3	0	0.0	12	1.2
Vancomycin resistant Enterococcus (VRE)	0	0.0	0	0.0	0	0.0	1	0.5	3	1.1	4	1.4	8	0.8
Enteric, Foodborne, and Waterborne Diseases														
Botulism	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	9	21.3	11	11.6	15	13.2	37	20.1	63	24.0	57	20.0	192	19.6
Cryptosporidiosis	1	2.4	3	3.2	11	9.7	10	5.4	8	3.0	1	0.4	34	3.5
Cyclosporiasis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Giardiasis	1	2.4	5	5.3	7	6.2	16	8.7	31	11.8	28	9.8	88	9.0
Hepatitis A	0	0.0	1	1.1	1	0.9	0	0.0	0	0.0	0	0.0	2	0.2
Listeriosis - Invasive	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	1.1	3	0.3
Salmonellosis	6	14.2	4	4.2	16	14.1	22	11.9	36	13.7	68	23.9	152	15.5
Shigellosis	0	0.0	0	0.0	0	0.0	0	0.0	1	0.4	0	0.0	1	0.1
Typhoid*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Verotoxigenic E. coli	0	0.0	1	1.1	0	0.0	1	0.5	0	0.0	0	0.0	2	0.2
Sexually Transmitted Infections														
Chlamydia	1	2.4	2	2.1	1386	1219.9	674	366.0	91	34.6	5	1.8	2159	219.9
Gonorrhea	0	0.0	0	0.0	35	30.8	42	22.8	11	4.2	0	0.0	88	9.0
Syphilis - Infectious	0	0.0	0	0.0	3	2.6	15	8.1	8	3.0	3	1.1	29	3.0
Syphilis - Non-Infectious or Stage Pending	0	0.0	0	0.0	2	1.8	6	3.2	8	3.1	6	2.2	22	2.2
Vaccine Preventable Diseases														
Acute Flaccid Paralysis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Haemophilus influenzae Type b Invasive Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Measles	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Pertussis	6	14.2	6	6.4	1	0.9	0	0.0	0	0.0	0	0.0	13	1.3
Tetanus	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vectorborne and Other Zoonoses														
Lyme Disease - Confirmed	3	7.1	43	45.5	10	8.8	14	7.6	69	26.3	94	33.0	233	23.7
Lyme Disease - Probable	5	11.8	12	12.7	5	4.4	21	11.4	71	27.0	98	34.4	212	21.6
Malaria	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	1	0.1
West Nile Virus	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
TOTAL	44		106		1585		1149		785		1233		4902	

Note: Notifiable diseases with no reported cases in the last 10 years (marked with a * in Appendix A) and influenza and COVID-19 cases are not included in this table

TABLE 3b: Notifiable diseases reported in Nova Scotia in 2021 by age group: Number of reports and age-specific rates per 100,000 population

Condition	Age Group (Years)												Total NS			
	0-4		5-14		15-24		25-39		40-59		60+		n	Rate		
	n	Rate	n	Rate	n	Rate	n	Rate	n	Rate	n	Rate				
Bloodborne Pathogens																
Acquired Immune Deficiency Syndrome (AIDS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis B - Acute	0	0.0	0	0.0	0	0.0	0	0.0	2	0.8	1	0.3	3	0.3	3	0.3
Hepatitis B - Chronic	0	0.0	0	0.0	5	4.5	3	1.6	8	3.1	3	1.0	19	1.9	19	1.9
Hepatitis C	1	2.4	0	0.0	15	13.4	139	73.2	98	37.7	25	8.5	278	28.0	278	28.0
Human Immunodeficiency Virus (HIV)	0	0.0	0	0.0	3	2.7	2	1.1	10	3.8	1	0.3	16	1.6	16	1.6
Direct Contact, Respiratory Routes, and Through the Provision of Health Care																
Clostridium difficile	3	7.2	5	5.2	43	38.4	85	44.8	172	66.1	654	223.2	962	97.0	962	97.0
Creutzfeldt-Jakob Disease - Classic	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Group A Streptococcal Disease Invasive-Severe	0	0.0	0	0.0	0	0.0	0	0.0	1	0.4	2	0.7	3	0.3	3	0.3
Group A Streptococcal Disease Invasive-Non-Severe	0	0.0	0	0.0	0	0.0	1	0.5	3	1.2	1	0.3	5	0.5	5	0.5
Group B Streptococcal Disease of the Newborn	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Legionellosis	0	0.0	0	0.0	0	0.0	0	0.0	7	2.7	8	2.7	15	1.5	15	1.5
Meningitis - Bacterial	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Meningococcal Disease Invasive	1	2.4	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0	2	0.2	2	0.2
Methicillin Resistant Staphylococcus Aureus (MRSA)	6	14.5	5	5.2	19	17.0	92	48.5	118	45.3	334	114.0	574	57.9	574	57.9
Pneumococcal Disease Invasive	4	9.6	0	0.0	0	0.0	6	3.2	24	9.2	53	18.1	87	8.8	87	8.8
Tuberculosis	0	0.0	0	0.0	8	7.1	4	2.1	2	0.8	1	0.3	15	1.5	15	1.5
Vancomycin resistant Enterococcus (VRE)	0	0.0	0	0.0	0	0.0	0	0.0	3	1.2	6	2.0	9	0.9	9	0.9
Enteric, Foodborne, and Waterborne Diseases																
Botulism	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	17	41.0	10	10.5	27	24.1	45	23.7	89	34.2	96	32.8	285	28.7	285	28.7
Cryptosporidiosis	1	2.4	4	4.2	3	2.7	5	2.6	3	1.2	3	1.0	19	1.9	19	1.9
Cyclosporiasis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Giardiasis	3	7.2	5	5.2	8	7.1	21	11.1	25	9.6	37	12.6	99	10.0	99	10.0
Hepatitis A	0	0.0	0	0.0	1	0.9	0	0.0	1	0.4	1	0.3	3	0.3	3	0.3
Listeriosis - Invasive	0	0.0	0	0.0	0	0.0	0	0.0	1	0.4	3	1.0	4	0.4	4	0.4
Salmonellosis	3	7.2	6	6.3	14	12.5	17	9.0	23	8.8	32	10.9	95	9.6	95	9.6
Shigellosis	0	0.0	0	0.0	0	0.0	2	1.1	1	0.4	1	0.3	4	0.4	4	0.4
Typhoid*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Verotoxigenic E. coli	1	2.4	1	1.0	1	0.9	1	0.5	0	0.0	2	0.7	6	0.6	6	0.6
Sexually Transmitted Infections																
Chlamydia	0	0.0	2	2.1	1347	1202.9	656	345.6	64	24.6	3	1.0	2072	208.9	2072	208.9
Gonorrhoea	0	0.0	0	0.0	27	24.1	31	16.3	9	3.5	0	0.0	67	6.8	67	6.8
Syphilis - Infectious	0	0.0	0	0.0	2	1.8	6	3.2	6	2.3	1	0.3	15	1.5	15	1.5
Syphilis - Non-Infectious or Stage Pending	0	0.0	0	0.0	7	6.3	12	6.3	5	1.9	0	0.0	24	2.0	24	2.0
Vaccine Preventable Diseases																
Acute Flaccid Paralysis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Haemophilus influenzae Type b Invasive Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Measles	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Pertussis	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	1	0.1	1	0.1
Tetanus	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vectorborne and Other Zoonoses																
Lyme Disease - Confirmed	9	21.7	69	72.3	24	21.4	68	35.8	154	59.2	182	62.1	506	51.0	506	51.0
Lyme Disease - Probable	2	4.8	15	15.7	5	4.5	11	5.8	19	7.3	36	12.3	88	8.9	88	8.9
Malaria	1	2.4	0	0.0	0	0.0	0	0.0	1	0.4	0	0.0	2	0.2	2	0.2
West Nile Virus	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
TOTAL	52		122		1560		1208		849		1486		5278			

Notes: Notifiable diseases with no reported cases in the last 10 years (marked with a * in Appendix A) and influenza and COVID-19 cases are not included in this table. Excludes 1 case of campylobacteriosis with no reported age.

TABLE 4a: Notifiable diseases reported in Nova Scotia in 2020: Number of reports and sex-specific rates per 100,000 population

Condition	Sex				Total NS	
	Female		Male		n	Rate
	n	Rate	n	Rate		
Bloodborne Pathogens						
Acquired Immune Deficiency Syndrome (AIDS)	1	0.2	0	0.0	1	0.1
Hepatitis B - Acute	3	0.6	3	0.6	6	0.6
Hepatitis B - Chronic	5	1.0	9	1.9	14	1.4
Hepatitis C	87	17.4	169	35.1	257	26.2
Human Immunodeficiency Virus (HIV)	6	1.2	7	1.5	13	1.3
Direct Contact, Respiratory Routes, and Through the Provision of Health Care						
Clostridium difficile	485	96.8	335	69.7	820	83.5
Creutzfeldt-Jakob Disease - Classic	0	0.0	0	0.0	0	0.0
Group A Streptococcal Disease Invasive-Severe	2	0.4	4	0.8	6	0.6
Group A Streptococcal Disease Invasive-Non-Severe	9	1.8	7	1.5	16	1.6
Group B Streptococcal Disease of the Newborn	0	0.0	0	0	0	0.0
Legionellosis	0	0.0	6	1.2	6	0.6
Meningitis - Bacterial	0	0.0	0	0.0	0	0.0
Meningococcal Disease Invasive	2	0.4	1	0.2	3	0.3
Methicillin Resistant Staphylococcus Aureus (MRSA)	211	42.1	248	51.6	459	46.7
Pneumococcal Disease Invasive	24	4.8	26	5.4	50	5.1
Tuberculosis	4	0.8	8	1.7	12	1.2
Vancomycin resistant Enterococcus (VRE)	3	0.6	5	1.0	8	0.8
Enteric, Foodborne, and Waterborne Diseases						
Botulism	0	0.0	0	0.0	0	0.0
Campylobacteriosis	75	15	117	24.3	192	19.6
Cryptosporidiosis	23	4.6	11	2.3	34	3.5
Cyclosporiasis	0	0.0	0	0.0	0	0.0
Giardiasis	44	8.8	44	9.1	88	9.0
Hepatitis A	1	0.2	1	0.2	2	0.2
Listeriosis - Invasive	2	0.4	1	0.2	3	0.3
Salmonellosis	95	19	57	11.9	152	15.5
Shigellosis	1	0.2	0	0.0	1	0.1
Typhoid*	0	0.0	0	0.0	0	0.0
Verotoxigenic E. coli	2	0.4	0	0.0	2	0.2
Sexually Transmitted Infections						
Chlamydia	1388	277.1	769	159.9	2159	219.9
Gonorrhea	36	7.2	52	10.8	88	9.0
Syphilis - Infectious	4	0.8	25	5.2	29	3.0
Syphilis - Non-Infectious or Stage Pending	7	1.4	15	3.1	22	2.2
Vaccine Preventable Diseases						
Acute Flaccid Paralysis	0	0.0	0	0.0	0	0.0
Haemophilus influenzae Type b Invasive Disease	0	0.0	0	0.0	0	0.0
Measles	0	0.0	0	0.0	0	0.0
Mumps	0	0.0	0	0.0	0	0.0
Pertussis	6	1.2	7	1.5	13	1.3
Tetanus	0	0.0	0	0.0	0	0.0
Vectorborne and Other Zoonoses						
Lyme Disease - Confirmed	106	21.2	127	26.4	233	23.7
Lyme Disease - Probable	96	19.2	116	24.1	212	21.6
Malaria	0	0.0	1	0.2	1	0.1
West Nile Virus	0	0.0	0	0.0	0	0.0
TOTAL	2728		2171		4902	

Notes: Notifiable diseases with no reported cases in the last 10 years (marked with a * in Appendix A) and influenza and COVID-19 cases are not included in this table. Excludes 1 hepatitis C and 2 chlamydia cases with no reported sex.

TABLE 4b: Notifiable diseases reported in Nova Scotia in 2021: Number of reports and sex-specific rates per 100,000 population

Condition	Sex				Total NS	
	Female		Male		n	Rate
	n	Rate	n	Rate		
Bloodborne Pathogens						
Acquired Immune Deficiency Syndrome (AIDS)	0	0.0	0	0.0	0	0.0
Hepatitis B - Acute	1	0.2	2	0.4	3	0.3
Hepatitis B - Chronic	8	1.6	11	2.3	19	1.9
Hepatitis C	96	19.0	182	37.5	278	28.0
Human Immunodeficiency Virus (HIV)	3	0.6	13	2.7	16	1.6
Direct Contact, Respiratory Routes, and Through the Provision of Health Care						
Clostridium difficile	541	106.9	421	86.6	962	97.0
Creutzfeldt-Jakob Disease - Classic	0	0.0	0	0.0	0	0.0
Group A Streptococcal Disease Invasive-Severe	1	0.2	2	0.4	3	0.3
Group A Streptococcal Disease Invasive-Non-Severe	0	0	5	1.0	5	0.5
Group B Streptococcal Disease of the Newborn	0	0.0	0	0.0	0	0.0
Legionellosis	7	1.4	8	1.6	15	1.5
Meningitis - Bacterial	0	0.0	0	0.0	0	0.0
Meningococcal Disease Invasive	0	0	2	0.4	2	0.2
Methicillin Resistant Staphylococcus Aureus (MRSA)	274	54.1	300	61.7	574	57.9
Pneumococcal Disease Invasive	29	5.7	58	11.9	87	8.8
Tuberculosis	6	1.2	9	1.9	15	1.5
Vancomycin resistant Enterococcus (VRE)	1	0.2	8	1.6	9	0.9
Enteric, Foodborne, and Waterborne Diseases						
Botulism	0	0.0	0	0.0	0	0.0
Campylobacteriosis	132	26.1	152	31.3	285	28.7
Cryptosporidiosis	12	2.4	7	1.4	19	1.9
Cyclosporiasis	0	0	0	0.0	0	0.0
Giardiasis	43	8.5	56	11.5	99	10.0
Hepatitis A	1	0.2	2	0.4	3	0.3
Listeriosis - Invasive	4	0.8	0	0.0	4	0.4
Salmonellosis	53	10.5	42	8.6	95	9.6
Shigellosis	1	0.2	3	0.6	4	0.4
Typhoid*	0	0.0	0	0.0	0	0.0
Verotoxigenic E. coli	2	0.4	4	0.8	6	0.6
Sexually Transmitted Infections						
Chlamydia	1359	268.5	713	146.7	2072	208.9
Gonorrhea	40	7.9	27	5.6	67	6.8
Syphilis - Infectious	1	0.2	14	2.9	15	1.5
Syphilis - Non-Infectious or Stage Pending	4	0.8	20	4.1	24	2.0
Vaccine Preventable Diseases						
Acute Flaccid Paralysis	0	0.0	0	0.0	0	0.0
Haemophilus influenzae Type b Invasive Disease	0	0.0	0	0.0	0	0.0
Measles	0	0.0	0	0.0	0	0.0
Mumps	0	0.0	0	0.0	0	0.0
Pertussis	1	0.2	0	0.0	1	0.1
Tetanus	0	0.0	0	0.0	0	0.0
Vectorborne and Other Zoonoses						
Lyme Disease - Confirmed	227	44.8	279	57.4	506	51.0
Lyme Disease - Probable	38	7.5	50	10.3	88	8.9
Malaria	1	0.2	1	0.2	2	0.2
West Nile Virus	0	0.0	0	0.0	0	0.0
TOTAL	2886		2391		5278	

Notes: Notifiable diseases with no reported cases in the last 10 years (marked with a * in Appendix A) and influenza and COVID-19 cases are not included in this table. Excludes 1 campylobacter case with no reported sex.